

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|----------------------------------|
| Name of entity | Actinogen Medical Limited |
| ABN | 14 086 778 476 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------------|
| Name of Director | Dr George Morstyn |
| Date of last notice | 5 June 2018 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | 1. Direct 2. Indirect 3. Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | 2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary 3. George Morstyn & Rosa Morstyn <Morstyn Family Trust A/C> - Beneficiary |
| Date of change | 13 December 2018 |
| No. of securities held prior to change | 1. 1,500,000 unlisted options exercisable at \$0.10 each on or before 1 December 2022 and subject to vesting conditions. 2. Nil. 3. 200,000 fully paid ordinary shares. |
| Class | 1. Unlisted options exercisable at \$0.085 each on or before 27 November 2023 and subject to vesting conditions. |
| Number acquired | 1,500,000 |
| Number disposed | - |
| Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Nil. |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| No. of securities held after change | <ol style="list-style-type: none"> 1. 1,500,000 unlisted options exercisable at \$0.10 each on or before 1 December 2022 and subject to vesting conditions. 1,500,000 unlisted options exercisable at \$0.085 each on or before 27 November 2023 and subject to vesting conditions. 2. 200,000 fully paid ordinary shares. 3. Nil. |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of unlisted options pursuant to shareholder approval at the annual general meeting held on 28 November 2018. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | N/A |
| Interest after change | N/A |

Part 3 – +Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.